Morphotek Overview

  • Year Founded
  • 2000

Year Founded

  • Status
  • Acquired/​Merged

  • Employees
  • 104

Employees

  • Latest Deal Type
  • M&A

  • Latest Deal Amount
  • $325M

  • Investors
  • 1

Morphotek General Information

Description

Developer of therapeutic monoclonal antibodies for the treatment of cancer, inflammatory, and infectious diseases. The company conducts research and clinical development programs on its own drug candidates for ailments such as ovarian and pancreatic cancers, rheumatoid arthritis, and asthma.

Contact Information

Ownership Status
Acquired/Merged
Financing Status
Formerly VC-backed
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Acquirer
Corporate Office
  • 210 Welsh Pool Road
  • Exton, PA 19341
  • United States

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Morphotek Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
6. Merger/Acquisition 17-Apr-2007 $325M 0000 00000 Completed Clinical Trials - Phase 2
5. Later Stage VC (Series D) 13-Oct-2006 0000 0000 000.00 Completed Clinical Trials - Phase 2
4. Later Stage VC (Series C) 19-Feb-2004 0000 0000 000.00 Completed Clinical Trials - Phase 2
3. Early Stage VC (Series B) 15-Aug-2001 0000 0000 000.00 Completed Product Development
2. Early Stage VC (Series A) 01-May-2001 $2M $2M 000.00 Completed Product Development
1. Accelerator/Incubator Completed Product Development
To view Morphotek’s complete valuation and funding history, request access »

Morphotek Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series D 000,000,000 00.000000 00 00.00 00.00 00.00 00.000
Series C 00,000,000 00.000000 00 00.00 00.00 00.00 00.000
Series B 9,219,592 $0.001000 8% $1.07 $1.07 $0.58 9.01%
Series A 2,040,830 $0.001000 8% $0.98 $0.98 $0.57 1.88%
To view Morphotek’s complete cap table history, request access »

Morphotek Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer of therapeutic monoclonal antibodies for the treatment of cancer, inflammatory, and infectious diseases. The c
Drug Discovery
Exton, PA
104 As of 2010
0000
0000 0000-00-00
000000&0 0000

000000

nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. D
0000 000000000
Emeryville, CA
000 As of 0000
00000
000000000 00000

000000

isi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit i
0000 000000000
Gaithersburg, MD
00 As of 0000
000.00
000000 - 000 000.00
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Morphotek Competitors (116)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Gritstone bio Formerly VC-backed Emeryville, CA 000 00000 000000000 00000
Altimmune Corporate Backed or Acquired Gaithersburg, MD 00 000.00 000000 - 000 000.00
Light Chain Bioscience Private Equity-Backed Geneva, Switzerland 00 00000 00000000000 00000
NexImmune Formerly VC-backed Gaithersburg, MD 00 00000 00000000 00000
Inovio Pharmaceuticals Corporation Plymouth Meeting, PA 000 000.00 00000000 000.00
You’re viewing 5 of 116 competitors. Get the full list »

Morphotek Patents

Morphotek Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-10941431-B2 Lysine conjugated immunoglobulins Active 10-Jun-2016 000000000 0
US-20180044711-A1 Lysine conjugated immunoglobulins Active 10-Jun-2016 000000000
US-20210171998-A1 Lysine conjugated immunoglobulins Active 10-Jun-2016 000000000
US-11753669-B2 Lysine conjugated immunoglobulins Active 10-Jun-2016 00000000000 00
US-20200297860-A1 Eribulin-based antibody-drug conjugates and methods of use Inactive 02-Mar-2016 A61K47/6803
To view Morphotek’s complete patent history, request access »

Morphotek Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Morphotek Former Investors (18)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Applied Genomic Technology Capital Fund Venture Capital Minority 000 0000 000000 0
Ben Franklin Technology Partners of Southeastern Pennsylvania Venture Capital Minority 000 0000 000000 0
Burrill & Co Merchant Banking Firm Minority 000 0000 000000 0
CB Health Ventures Venture Capital Minority 000 0000 000000 0
CDIB Capital Group Venture Capital Minority 000 0000 000000 0
You’re viewing 5 of 18 investors. Get the full list »

Morphotek Acquisitions (3)

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
Transmolecular (Scorpion Venom platform) 05-Apr-2011 0000000000 Biotechnology
Transmolecular (Tumor Targeting Platform) 05-Apr-2011 0000000000 Pharmaceuticals
Transmolecular 01-Mar-2011 Merger/Acquisition Biotechnology
To view Morphotek’s complete acquisitions history, request access »

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »